Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27;9(6):ofac171.
doi: 10.1093/ofid/ofac171. eCollection 2022 Jun.

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Jane C Figueiredo  1 Fred R Hirsch  2 Lawrence H Kushi  3 Wendy N Nembhard  4 James M Crawford  5 Nicholas Mantis  6 Laurel Finster  1 Noah M Merin  7 Akil Merchant  7 Karen L Reckamp  1 Gil Y Melmed  8 Jonathan Braun  8 Dermot McGovern  8 Samir Parekh  2 Douglas A Corley  3 Namvar Zohoori  4 Benjamin C Amick  4 Ruofei Du  4 Peter K Gregersen  5 Betty Diamond  5 Emanuela Taioli  2 Carlos Sariol  9 Ana Espino  9 Daniela Weiskopf  10 Alba Gifoni  10 James Brien  11 William Hanege  12 Marc Lipsitch  12 David A Zidar  13 Ann Scheck McAlearney  14 Ania Wajnberg  15 Joshua LaBaer  16 E Yvonne Lewis  17 Raquel A Binder  18 Ann M Moormann  18 Catherine Forconi  18 Sarah Forrester  19 Jennifer Batista  19 John Schieffelin  20 Dongjoo Kim  21 Giulia Biancon  22 Jennifer VanOudenhove  22 Stephanie Halene  22 Rong Fan  21 Dan H Barouch  23 Galit Alter  24 Swetha Pinninti  25 Suresh B Boppana  25 Sunil K Pati  25 Misty Latting  25 Andrew H Karaba  26 John Roback  27 Rafick Sekaly  27 Andrew Neish  27 Ahnalee M Brincks  28 Douglas A Granger  29 Amy B Karger  30 Bharat Thyagarajan  31 Stefani N Thomas  30 Sabra L Klein  31 Andrea L Cox  26 Todd Lucas  32 Debra Furr-Holden  32 Kent Key  32 Nicole Jones  32 Jens Wrammerr  33 Mehul Suthar  33 Serre Yu Wong  34 Natalie M Bowman  35 Viviana Simon  36 Lynne D Richardson  37 Russell McBride  38 Florian Krammer  36 Meenakshi Rana  38 Joshua Kennedy  39 Karl Boehme  40 Craig Forrest  40 Steve W Granger  41 Christopher D Heaney  42 Maria Knight Lapinski  43 Shannon Wallet  44 Ralph S Baric  45 Luca Schifanella  46 Marcos Lopez  47 Soledad Fernández  48 Eben Kenah  49 Ashish R Panchal  50 William J Britt  51 Iñaki Sanz  52 Madhav Dhodapkar  52 Rafi Ahmed  53 Luther A Bartelt  35 Alena J Markmann  35 Jessica T Lin  35 Robert S Hagan  35 Matthew C Wolfgang  54 Jacek Skarbinski  3
Affiliations

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Jane C Figueiredo et al. Open Forum Infect Dis. .

Abstract

Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies.

Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders).

Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes.

Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

Keywords: COVID-19; SARS-CoV-2; SeroNet; cohort; epidemiology; serosurveillance.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Primary US Institutions Participating in SeroNet Studies.

Similar articles

  • The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.
    Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, Pinto LA, Premkumar L, Roback JD, Binder RA, Boehme KW, Boppana S, Cordon-Cardo C, Crawford JM, Daiss JL, Dupuis AP 2nd, Espino AM, Firpo-Betancourt A, Forconi C, Forrest JC, Girardin RC, Granger DA, Granger SW, Haddad NS, Heaney CD, Hunt DT, Kennedy JL, King CL, Krammer F, Kruczynski K, LaBaer J, Lee FE, Lee WT, Liu SL, Lozanski G, Lucas T, Mendu DR, Moormann AM, Murugan V, Okoye NC, Pantoja P, Payne AF, Park J, Pinninti S, Pinto AK, Pisanic N, Qiu J, Sariol CA, Simon V, Song L, Steffen TL, Stone ET, Styer LM, Suthar MS, Thomas SN, Thyagarajan B, Wajnberg A, Yates JL, Sobhani K. Karger AB, et al. mSphere. 2022 Aug 31;7(4):e0019322. doi: 10.1128/msphere.00193-22. Epub 2022 Jun 15. mSphere. 2022. PMID: 35703544 Free PMC article.
  • The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.
    Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, Pinto LA, Premkumar L, Roback JD, Binder RA, Boehme KW, Boppana S, Cordon-Cardo C, Crawford JM, Daiss JL, Dupuis AP 2nd, Espino AM, Firpo-Betancourt A, Forconi C, Forrest JC, Girardin RC, Granger DA, Granger SW, Haddad NS, Heaney CD, Hunt DT, Kennedy JL, King CL, Krammer F, Kruczynski K, LaBaer J, Lee FE, Lee WT, Liu SL, Lozanski G, Lucas T, Mendu DR, Moormann AM, Murugan V, Okoye NC, Pantoja P, Payne AF, Park J, Pinninti S, Pinto AK, Pisanic N, Qiu J, Sariol CA, Simon V, Song L, Steffen TL, Stone ET, Styer LM, Suthar MS, Thomas SN, Thyagarajan B, Wajnberg A, Yates JL, Sobhani K. Karger AB, et al. medRxiv [Preprint]. 2022 Mar 14:2022.02.27.22271399. doi: 10.1101/2022.02.27.22271399. medRxiv. 2022. Update in: mSphere. 2022 Aug 31;7(4):e0019322. doi: 10.1128/msphere.00193-22. PMID: 35262095 Free PMC article. Updated. Preprint.
  • The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop.
    Hempel H, Mantis N, Heaney CD, Pinto LA. Hempel H, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2253598. doi: 10.1080/21645515.2023.2253598. Hum Vaccin Immunother. 2023. PMID: 37695268 Free PMC article.
  • Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.
    Crisan-Dabija R, Grigorescu C, Pavel CA, Artene B, Popa IV, Cernomaz A, Burlacu A. Crisan-Dabija R, et al. Can Respir J. 2020 Sep 5;2020:1401053. doi: 10.1155/2020/1401053. eCollection 2020. Can Respir J. 2020. PMID: 32934758 Free PMC article. Review.
  • A compendium answering 150 questions on COVID-19 and SARS-CoV-2.
    Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, Antó JM, Arcolaci A, Azkur AK, Azkur D, Beken B, Boccabella C, Bousquet J, Breiteneder H, Carvalho D, De Las Vecillas L, Diamant Z, Eguiluz-Gracia I, Eiwegger T, Eyerich S, Fokkens W, Gao YD, Hannachi F, Johnston SL, Jutel M, Karavelia A, Klimek L, Moya B, Nadeau KC, O'Hehir R, O'Mahony L, Pfaar O, Sanak M, Schwarze J, Sokolowska M, Torres MJ, van de Veen W, van Zelm MC, Wang Y, Zhang L, Jiménez-Saiz R, Akdis CA. Riggioni C, et al. Allergy. 2020 Oct;75(10):2503-2541. doi: 10.1111/all.14449. Epub 2020 Jul 20. Allergy. 2020. PMID: 32535955 Free PMC article. Review.

Cited by

References

    1. Lurie N, Saville M, Hatchett R, Halton J.. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020; 382:1969–73. - PubMed
    1. National Cancer Institute. Serological Sciences network to study COVID Immune response. Available at: https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-res.... Accessed 2021.
    1. Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403–16. - PMC - PubMed
    1. Mullard A. COVID-19 vaccine development pipeline gears up. Lancet 2020; 395:1751–2. - PMC - PubMed